Pomerantz LLP announced investigations into securities fraud claims against SELLAS Life Sciences, JinkoSolar, and Stitch Fix. The investigation into SELLAS focuses on delayed release of phase 3 clinical trial results for Galinpepimut-S, which triggered an 13.15% stock price decline on August 28, 2026.
SLS
SELLAS Life Sciences Group, Inc. · NASDAQ
News
1 latestHeadlines link to the publisher. Not investment advice.
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Community
7 daysNo sentiment yet
Posts 24h
0
Replies 24h
0
Watchers
0
Board · $SLS · 0 threads
Sign in to post on $SLS
No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.